IP Library Patent Application 18806201
Patent Application
App. No. 18/806,201

Method for Measuring Fibroblast Growth Factor-23 and Reagent Therefor

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/806,201
Abstract

A method for measuring fibroblast growth factor-23 (FGF-23) in a sample, which comprise the following steps: (1) reacting, in an aqueous medium, FGF-23 in a sample with magnetic particles, a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particles an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23, FGF-23, and the second antibody or a fragment thereof which binds to FGF-23; (2) collecting the magnetic particles in the reaction mixture after step (1) by magnetic force, and separating the magnetic particles collected by magnetic force from the other components; and (3) measuring the immunocomplex on the magnetic particles separated in step (2). The present invention provides a method for measuring FGF-23 in a sample, which have a high sensitivity and have a wide measurement range.

Claims (19)

1 . A method for measuring fibroblast growth factor-23 (hereinafter indicated as FGF-23) in a sample, wherein the method comprises the steps of:

(1) reacting, in an aqueous medium, FGF-23 in a sample with a magnetic particle, a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particle an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23, FGF-23, and the second antibody or a fragment thereof which binds to FGF-23, wherein the sample comprises FGF-23 in a concentration ranging from 1,000 pg/mL to 10,000 pg/mL;

(2) collecting the magnetic particle in the reaction mixture after step (1) by magnetic force,

and separating the magnetic particle collected by magnetic force from the other components; and

(3) measuring the immunocomplex on the magnetic particle separated in step (2).

2 . The method for separating a bonded wafer according to claim 1 , wherein the epitaxial functional layer has a light emitting device structure.

3 . A method for measuring fibroblast growth factor-23 (hereinafter indicated as FGF-23) in a sample, wherein the method comprises the steps of:

(1) reacting, in an aqueous medium, FGF-23 in a sample with a magnetic particle, a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particle an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23, FGF-23, and the second antibody or a fragment thereof which binds to FGF-23,

(a) wherein the sample comprises FGF-23 in a concentration ranging from 5 pg/mL to 10,000 pg/mL when subjected to the reaction, and/or

(b) the sample comprising FGF-23 in a concentration ranging from 5 pg/mL to 10,000 pg/mL is directly subjected to the reaction;

(2) collecting the magnetic particle in the reaction mixture after step (1) by magnetic force,

and separating the magnetic particle collected by magnetic force from the other components; and

(3) measuring the immunocomplex on the magnetic particle separated in step (2).

4 . A method for measuring fibroblast growth factor-23 (hereinafter indicated as FGF-23) in a sample, wherein the method comprises the steps of:

(1) reacting, in an aqueous medium, FGF-23 in a sample with a magnetic particle, a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particle an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23, FGF-23, and the second antibody or a fragment thereof which binds to FGF-23, wherein the sample comprises FGF-23 in a concentration ranging from 5 pg/mL to 10,000 pg/mL;

(2) collecting the magnetic particle in the reaction mixture after step (1) by magnetic force,

and separating the magnetic particle collected by magnetic force from the other components;

(3) measuring the immunocomplex on the magnetic particle separated in step (2); and

(4) determining a concentration of FGF-23 in the sample by comparing a measured value obtained in (c) with a calibration curve prepared using known concentrations of FGF-23 ranging from 5 pg/mL to 10,000 pg/mL.

Assignments (4)
CHANGE OF NAME Recorded Jun 13, 2025
From: MINARIS MEDICAL CO., LTD.
To: CANON MEDICAL DIAGNOSTICS CORPORATION
Reel/Frame 071580/0058 →
CHANGE OF NAME Recorded Jun 11, 2025
From: HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD.
To: MINARIS MEDICAL CO., LTD.
Reel/Frame 071557/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2024
From: UZAWA, KOJI; SUZUKI, EMIKO; IKEDA, KAZUYUKI; MORITA, KAZUKI
To: KYOWA MEDEX CO., LTD.
Reel/Frame 068522/0413 →
CHANGE OF NAME Recorded Sep 9, 2024
From: KYOWA MEDEX CO., LTD.
To: HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD.
Reel/Frame 068894/0012 →